Catastrophic slab loss in southwestern Pangea preserved in the mantle and igneous record.

Nat Commun

Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Capital Federal, Argentina.

Published: February 2022

The Choiyoi Magmatic Province represents a major episode of silicic magmatism in southwestern Pangea in the mid-Permian-Triassic, the origin of which remains intensely debated. Here, we integrate plate-kinematic reconstructions and the lower mantle slab record beneath southwestern Pangea that provide clues on late Paleozoic-Mesozoic subducting slab configurations. Also, we compile geochronological information and analyze geochemical data using tectono-magmatic discrimination diagrams. We demonstrate that this magmatic event resulted from a large-scale slab loss. This is supported by a paleogeographic coincidence between a reconstructed 2,800-3,000-km-wide slab gap and the Choiyoi Magmatic Province and geochemical data indicating a slab break-off fingerprint in the latter. The slab break-off event is compatible with Permian paleogeographic modifications in southwestern Pangea. These findings render the Choiyoi Magmatic Province the oldest example of a geophysically constrained slab loss event and open new avenues to assess the geodynamic setting of silicic large igneous provinces back to the late Paleozoic.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817029PMC
http://dx.doi.org/10.1038/s41467-022-28290-zDOI Listing

Publication Analysis

Top Keywords

southwestern pangea
16
slab loss
12
choiyoi magmatic
12
magmatic province
12
geochemical data
8
slab break-off
8
slab
7
catastrophic slab
4
southwestern
4
loss southwestern
4

Similar Publications

Article Synopsis
  • * The study reveals that RAS mutations transform specific blood cell progenitors (granulocyte-monocyte progenitors) that have already acquired other mutations, suggesting advanced leukemia can arise from different cell types than initial clones.
  • * RAS-mutant leukemia stem cells show resistance to the treatment drug venetoclax due to changes in gene expression, leading to worse treatment responses and relapses characterized by monocytic features, highlighting the impact of genetic drivers on therapy effectiveness.
View Article and Find Full Text PDF

Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.

Cancers (Basel)

January 2024

Division of Hematology-Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA.

Improvements in survival have been made over the past two decades for childhood acute myeloid leukemia (AML), but the approximately 40% of patients who relapse continue to have poor outcomes. A combination of checkpoint-inhibitor nivolumab and azacitidine has demonstrated improvements in median survival in adults with AML. This phase I/II study with nivolumab and azacitidine in children with relapsed/refractory AML (NCT03825367) was conducted through the Therapeutic Advances in Childhood Leukemia & Lymphoma consortium.

View Article and Find Full Text PDF

Catastrophic slab loss in southwestern Pangea preserved in the mantle and igneous record.

Nat Commun

February 2022

Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Capital Federal, Argentina.

The Choiyoi Magmatic Province represents a major episode of silicic magmatism in southwestern Pangea in the mid-Permian-Triassic, the origin of which remains intensely debated. Here, we integrate plate-kinematic reconstructions and the lower mantle slab record beneath southwestern Pangea that provide clues on late Paleozoic-Mesozoic subducting slab configurations. Also, we compile geochronological information and analyze geochemical data using tectono-magmatic discrimination diagrams.

View Article and Find Full Text PDF

There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!